Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. A high throughput sample preparation platform for genomic and epigenetic analysis

    SBC: Matchstick Technologies Inc.            Topic: 200

    Several types of cancers e g pancreatic and brain malignancies remain extremely lethal despite the introduction of chemotherapy more than years ago The hallmark of all cancers are somatic mutations which cannot be corrected In sharp contrast epigenetic changes essential contributors to tumorigenesis are pharmacologically reversible The ability to remedy detrimental epigenetic alteratio ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A Phase Clinical Trial Evaluating the Novel Small Molecule Immuno Oncology Antagonist SX Alone and With Pembrolizumab in Metastatic Melanoma

    SBC: Syntrix Biosystems, Inc.            Topic: 102

    The chemokine receptors CXCR and CXCR CXCR are validated as having essential roles in the growth survival motility invasion and angiogenesis of human melanoma which secretes abundant amounts of the corresponding chemokine ligands including CXCL Additionally abnormal cancer induced immunosuppressive myeloid derived suppressor cells MDSCs in the circulation and tumor correlate with ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Development of the first thermolytic to suppress shivering and seizure

    SBC: Be Cool Pharmaceutics LLC            Topic: NHLBI

    Summary The temperature management market is expected to reach $billion byyet no pharmaceutical has yet been developed specifically for this marketAadenosineA ARagonists are well known to attenuate seizure and protect the brain from injurybut development of these drugs has been limited by side effects including hypothermiabradycardia and hypotensionInspired by our discoveries thatN cyclohexyl aden ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Study of an Extended Patency Dialysis Access Graft

    SBC: HEALIONICS CORPORATION            Topic: 300

    Clinical Study of an Extended Patency Dialysis Access Graft PROJECT SUMMARY Objective The goals of this PAR Clinical Studies Fast Track SBIR proposal are to move a novel hemodialysis access graft design to k submission and upon k clearance conduct a patient clinical study to demonstrate improved performance compared to current synthetic grafts which have high rate of clot ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. "Grid-Tape": A High-Throughput Platform for Brain Connectomics and Nanoscale Structural Analysis

    SBC: Luxel Corporation            Topic: 101

    The wiring diagram of brain circuits is one of the foundational and fundamental questions of modern neuroscienceExtracting a circuit sized volume at synaptic resolution requires large scalehigh throughput imaging of many thin sections of brain tissueThe immediate goal of researchers is to capture and map a cubic millimeter of cortex at synaptic resolutionrequiring the collection and imaging oftiss ...

    SBIR Phase I 2017 Department of Health and Human Services
  6. NeuroPET HD: A low-cost, high performance neuro-PET imaging system

    SBC: PET/X LLC            Topic: 102

    This revised proposal is in response to PAR"BRAIN InitiativeDevelopmentOptimizationand Validation of Novel Tools and Technologies for Neuroscience Research"Our overall goal is to enable positron emission tomographyPETas a practical and effective quantitative tool in understanding brain function and healthIn vivo functional imaging of molecular tracers will play a key role in unraveling the physiol ...

    STTR Phase I 2017 Department of Health and Human Services
  7. HLS Potent novel inhibitor of fibrinolytic hemorrhage

    SBC: Translational Sciences Inc.            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest therapeutics that are of high programmatic interest HL Hemorrhage or bleeding is a serious or fatal complication of surgery Antifibrinolytic agents that inhibit plasmin mediated fibrinolysis can significantly reduce blood loss emergency reoperation morbidity and death in patients with severe hemor ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. " Channel Multimodal Ultrathin Flexible SFE for cancer diagnosis and therapy"

    SBC: VERAVANTI INC.            Topic: 102

    Summary channel multimodal ultrathin flexible SFE for cancer diagnosis and therapy Minimally invasive optical imaging is being advanced by molecular probes that enhance contrast using fluorescence The applications in cancer imaging are very broad ranging from early diagnosis of cancer to the guiding of interventions such as surgery The high sensitivity afforded by wide field fluorescence i ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Tolerance inducing Probiotic Platform

    SBC: VIRTICI LLC            Topic: NIAID

    Project Summary Our goal is to validate a novel Lactococcus lactis L lactis based platform to rapidly develop and deliver tolerance inducing therapeutics for the treatment of autoimmunity and allergy Autoimmune and allergic diseases such as Multiple Sclerosis MS Type Diabetes and food allergies affect of the world population and are continuing to rise These illnesses are the ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Tolerance Therapeutic for Treating Type Diabetes

    SBC: VIRTICI LLC            Topic: 200

    Project Summary Our goal is to develop VTC D as a novel tolerance inducing therapeutic for the treatment of Type Diabetes T D T D is an autoimmune disease characterized by the destruction of the insulin producing pancreatic beta cells While the etiology of T D remains undefined evidence suggests that autoimmunity to insulin is a major driver of disease initiation Each year over ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government